Amplify Weight Loss Drug & Treatment ETF (THNR) Price & Chart
THNR ETF Chart & Stats
- Day’s Range
- $24.85 - $24.97
- 52-Week Range
- $22.89 - $27.94
- Previous Close
- $24.92
- Volume
- 2,668
- Average Volume (3M)
- 1,266
- AUM
- 5.73M
- NAV
- 24.95
- Expense Ratio
- 0.59%
- Holdings Count
- 22
- Beta
- 0.64
- Inception Date
- May 21, 2024
- Last Dividend Ex-Date
- Dec 30, 2025
- Dividend Yield
- (1.66%)
- Shares Outstanding
- 230,000
- Standard Deviation
- N/A
ETF Overview
Amplify Weight Loss Drug & Treatment ETF
The Amplify Weight Loss Drug & Treatment ETF (THNR) is a specialized investment vehicle designed to capitalize on the burgeoning health care sector, with a distinct focus on the Pharmaceuticals, Biotechnology, and Life Sciences niche. This innovative ETF provides investors with targeted exposure to companies at the forefront of developing and commercializing groundbreaking weight loss drugs and treatment solutions. As global health trends increasingly emphasize the importance of weight management and obesity-related health issues, THNR strategically positions itself within a rapidly expanding market. By investing in a curated portfolio of firms leading the charge in medical research, drug development, and innovative treatment methodologies, this ETF offers a unique opportunity for investors seeking to benefit from advancements in health care technology and pharmaceuticals. Whether you're an investor looking to diversify your portfolio or seeking to support transformative health solutions, the Amplify Weight Loss Drug & Treatment ETF presents a compelling avenue for aligning financial growth with impactful, sector-specific developments.